Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Industry Today.
Press releases published on August 7, 2025
AMN Healthcare Announces Second Quarter 2025 Results
GlobeNewswire
·
August 7, 2025
Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02)/share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent …
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 …
TerrAscend Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Net Revenue totaled $65 million and Gross Profit Margin was 51.1% from continuing operations, excluding Michigan 12th consecutive quarter of positive Cash Flow from continuing operations and 8th consecutive quarter of positive Free Cash Flow¹ Announced …
Biodesix Announces Second Quarter 2025 Results and Highlights
GlobeNewswire
·
August 7, 2025
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. …
Apyx Medical Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 7, 2025
CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase 100,000 shares of common stock to John …
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 7, 2025
-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional …
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
August 7, 2025
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash …
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes
GlobeNewswire
·
August 7, 2025
BOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its …
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
GlobeNewswire
·
August 7, 2025
CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; …
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the Global Development Program for Atumelnant Across …
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
BOTHELL, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results …
Regeneron Announces Investor Conference Presentations
GlobeNewswire
·
August 7, 2025
TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Cantor Global Healthcare Conference 2025 at 1:35 p.m. ET on Wednesday, September 3, 2025 2025 Wells Fargo …
Kura Oncology Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
– FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with …
PacBio Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results: Q2 2025 Q2 2024 Revenue $39.8 million $36.0 million Instrument revenue $14.2 …
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12 Weeks Post …
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE …
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 7, 2025
DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non- …
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with first-in-human studies planned to initiate in 2025 China and European approval for zanidatamab in 2L HER2-positive biliary tract …
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter Currently in cohort 4 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers …
ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
GlobeNewswire
·
August 7, 2025
SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. …